In this article, Prof Peter Gibbs and Prof Svetlana Cherepanoff discuss the issues surrounding the clinical integration of NGS in Australia….
Cancer Type: Lung
NGS and precision oncology in Taiwan: insights from Dr Jan-Gowth Chang and Dr Jason CH Hsieh
NGS and digital applications for oncology management can help improve early cancer detection and prevention, reducing human and economic costs of the cancer. In this article, Dr Jan-Gowth Chang and Dr Jason CH Hsieh explore the current use of these technologies in Taiwan and their hopes for the future. …
NGS and precision oncology in India: insights from Dr Amit Rauthan
In this article, Dr Amit Rauthan shares insights on the challenges and opportunities for greater NGS adoption in India. …
Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia
This study aimed to evaluate the economic impact of upfront NGS compared to testing modalities in East Asian patients with mNSCLC, by using Hong Kong as an example. …
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
This study proposes a unified framework to classify targets for precision cancer medicine based on clinical evidence of utility, to aid oncologists in prioritising potential targets for clinical use when receiving reports of broad gene sequencing panels, and facilitate implementation of precision medicine in the clinical management of cancer….
The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular Tumour Board (MTB) was established to advance precision oncology in Hong Kong. A multicenter retrospective study investigated the feasibility of the HKU-HKSH MTB in determining genome-guided therapy for treatment-refractory solid cancers in Hong Kong….